DUBLIN, January 27, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/p54ckt/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Market for Personalized Gene Therapy Treatments for Cancer This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. As part of its data offering, the report provides disease incidence, gene therapy product developments and market forecasts for the following types of cancer:
These include:
Companies Mentioned:
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Advertisement
Research and Markets (http://www.researchandmarkets.com/research/p54ckt/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering.
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Market for Personalized Gene Therapy Treatments for Cancer This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. As part of its data offering, the report provides disease incidence, gene therapy product developments and market forecasts for the following types of cancer:
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Head & Neck
- Colorectal Cancer
- Leukemia Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Leukemia
- Pancreatic Cancer
- Prostate Cancer
- Ovarian Cancer
- Other Cancer
- Overview of Gene Therapy
- Overall Market Size and Forecast
- Cancer Therapeutic Market Totals
- Discussion of Somati vs. Germ Line Gene Therapy
- R&D Activities
- Company Profiles
These include:
- Adaptimmune Ltd.
- Advantagene, Inc.
- Amgen, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioCancell Ltd.
- Blubird Bio
- Celgene
- Celsion Corporation
- Chengdu Shi Endor Biological Engineering Technology Co., Ltd.
- Cold Genesys, Inc.
- Genprex, Inc.
- MaxiVax SA
- Momotaro-Gene, Inc.
- MultiVir, Inc.
- OncoSec Medical, Inc.
- Sevion Therapeutics, Inc.
- SynerGene Therapeutics, Inc.
- Takara Bio, Inc.
- Tocagen, Inc.
- VBL Therapeutics Ltd.
- Ziopharm Oncology, Inc.
Companies Mentioned:
- Advantagene, Inc.
- Amgen, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioCancell Ltd.
- Blubird Bio
- Celgene
- Celsion Corporation
- Chengdu Shi Endor Biological Engineering Technology Co., Ltd.
- Cold Genesys, Inc.
- Genprex, Inc.
- MaxiVax SA
- Momotaro-Gene, Inc.
- MultiVir, Inc.
- OncoSec Medical, Inc.
- Sevion Therapeutics, Inc.
- SynerGene Therapeutics, Inc.
- Takara Bio, Inc.
- Tocagen, Inc.
- VBL Therapeutics Ltd.
- Ziopharm Oncology, Inc.
- daptimmune Ltd.
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets